[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.173.36. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Rutter  M Incidence of autism spectrum disorders: changes over time and their meaning.  Acta Paediatr 2005;94 (1) 2- 15PubMedGoogle ScholarCrossref
2.
Croen  LAGrether  JKHoogstrate  JSelvin  S The changing prevalence of autism in California.  J Autism Dev Disord 2002;32 (3) 207- 215PubMedGoogle ScholarCrossref
3.
Fombonne  E The prevalence of autism.  JAMA 2003;289 (1) 87- 89PubMedGoogle ScholarCrossref
4.
Bernard  SEnayati  ARedwood  LRoger  HBinstock  T Autism: a novel form of mercury poisoning.  Med Hypotheses 2001;56 (4) 462- 471PubMedGoogle ScholarCrossref
5.
Blaxill  MFRedwood  LBernard  S Thimerosal and autism? a plausible hypothesis that should not be dismissed.  Med Hypotheses 2004;62 (5) 788- 794PubMedGoogle ScholarCrossref
6.
Immunization Safety Review Committee; Board on Health Promotion and Disease Prevention, Institute of Medicine of the National Academies, Immunization Safety Review: Vaccines and Autism.  Washington, DC National Academies Press2004;http://www.nap.edu/catalog/10997.html#toc. Accessed May 11, 2007
7.
Centers for Disease Control and Prevention, Notice to readers: thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service.  MMWR Morb Mortal Wkly Rep 1999;48 (26) 563- 565http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4826a3. Accessed May 11, 2007PubMedGoogle Scholar
8.
Parker  SKSchwartz  BTodd  JPickering  LK Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data.  Pediatrics 2004;114 (3) 793- 804[published correction appears in Pediatrics. 2005;115(1):200].PubMedGoogle ScholarCrossref
9.
US Food and Drug Administration, Thimerosal in vaccines. http://www.fda.gov/cber/vaccine/thimerosal. Accessed May 11, 2007
10.
Centers for Disease Control and Prevention, Notice to readers: update: supply of diphtheria and tetanus toxoids and acellular pertussis vaccine.  MMWR Morb Mortal Wkly Rep 2002;50 (51) 1159http://www.cdc.gov/MMWR/preview/mmwrhtml/mm5051a3. Accessed May 11, 2007Google Scholar
11.
Dayan  GHIskander  JGlasser  JEnglish-Bullard  RFullerton  KEChen  R Tracking vaccine lot lifecycles using reports to the Vaccine Adverse Event Reporting System (VAERS).  Pharmacoepidemiol Drug Saf 2005;14 (10) 671- 676PubMedGoogle ScholarCrossref
12.
Institute of Medicine of the National Academies, Thimerosal-containing vaccines and neurodevelopmental outcomes meeting agenda; Monday, July 16, 2001; Cambridge, Massachusetts. http://www.iom.edu/CMS/3793/4705/6694/7465.aspx. Accessed May 11, 2007
13.
Institute of Medicine of the National Academies, Immunization Safety Review Committee meeting 9: vaccines and autism: agenda and presentations; February 9, 2004; Washington, DC. http://www.iom.edu/CMS/3793/4705/17047/18065.aapx Accessed May 11, 2007
14.
Stehr-Green  PTull  PStellfield  MMortenson  PBSimpson  D Autism and thimerosal-containing vaccines: lack of consistent evidence for an association.  Am J Prev Med 2003;25 (2) 101- 106PubMedGoogle ScholarCrossref
15.
Madsen  KMLauritsen  MBPedersen  CBThorsen  PPlesner  AMAndersen  PHMortensen  PB Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data.  Pediatrics 2003;112 (3, pt 1) 604- 606PubMedGoogle ScholarCrossref
16.
Hviid  AStellfeld  MWohlfahrt  JMelbye  M Association between thimerosal-containing vaccine and autism.  JAMA 2003;290 (13) 1763- 1766PubMedGoogle ScholarCrossref
17.
Verstraeten  TDavis  RLDeStefano  FLieu  TARhodes  PHBlack  SBShinefield  HChen  RTVaccine Safety Datalink Team, Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases.  Pediatrics 2003;112 (5) 1039- 1048[published correction appears in Pediatrics. 2004;113(1):184].PubMedGoogle ScholarCrossref
18.
Heron  JGolding  JALSPAC Study Team, Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association.  Pediatrics 2004;114 (3) 577- 583PubMedGoogle ScholarCrossref
19.
Andrews  NMiller  EGrant  AStowe  JOsborne  VTaylor  B Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association.  Pediatrics 2004;114 (3) 584- 591PubMedGoogle ScholarCrossref
20.
Blaxill  M The rising incidence of autism: associations with thimerosal: slide 10 [presentation to the Institute of Medicine, July 16, 2001]. http://www.iom.edu/object.file/master/7/505/blaxill.pdf. Accessed May 11, 2007
21.
Geier  MRGeier  DA Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication.  Exp Biol Med (Maywood) 2003;228 (6) 660- 664PubMedGoogle Scholar
22.
Geier  DAGeier  MR An assessment of the impact of thimerosal on childhood neurodevelopmental disorders.  Pediatr Rehabil 2003;6 (2) 97- 102PubMedGoogle Scholar
23.
Geier  MRGeier  DA Pediatric MMR vaccination safety.  Int Pediatr 2003;18 (2) 203- 208Google Scholar
24.
Geier  MRGeier  DA Thimerosal in childhood vaccines, neurodevelopment disorders, and heart disease in the United States.  J Am Phys Surg 2003;8 (1) 6- 11http://www.jpands.org/vol8no1/geier.pdf. Accessed May 11, 2007Google Scholar
25.
Geier  DAGeier  MR A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism.  Med Sci Monit 2004;10 (3) PI33- PI39PubMedGoogle Scholar
26.
California Department of Health Services, Population, live births, deaths, maternal deaths, fetal deaths, and infant deaths, California, 1970-2004 [Table 1-1]. http://www.dhs.ca.gov/hisp/chs/OHIR/tables/datafiles/vsofca/0101.pdf. Accessed May 11, 2007
27.
California Department of Finance, Race/ethnic population with age and sex detail, 1990-1999 and 2000–2004. http://www.dof.ca.gov/HTML/DEMOGRAP/DRU_datafiles/DRU_DataFiles.php. Accessed May 11, 2007
28.
California Department of Developmental Services, Quarterly client characteristics report. http://www.dds.ca.gov/FactsStats/QuarterlyReports..cfm Accessed May 11, 2007
29.
Wessa  P Free statistics and forecasting software, Office for Research, Development, and Education, version 1.1.21. 2007;http://www.wessa.net/. Accessed May 11, 2007
30.
Geier  DAGeier  MR Early downward trends in neurodevelopmental disorders following removal of thimerosal-containing vaccines.  J Am Phys Surg 2006;11 (1) 8- 13http://www.jpands.org/vol11no1/geier.pdf. Accessed May 11, 2007Google Scholar
31.
Jick  HKaye  JA Autism and DPT vaccination in the United Kingdom.  N Engl J Med 2004;350 (26) 2722- 2723PubMedGoogle ScholarCrossref
32.
Fombonne  EZakarian  RBennett  AMeng  LMcLean-Heywood  D Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.  Pediatrics 2006;118 (1) e139- e150PubMedGoogle ScholarCrossref
33.
Miles  JHTakahashi  TN Lack of association between Rh status, Rh immune globulin in pregnancy and autism.  Am J Med Genet A 2007;143 (13) 1397- 1407PubMedGoogle ScholarCrossref
34.
California Department of Developmental Services, Data interpretation considerations and limitations. http://www.dds.ca.gov/FactsStats/docs/CDER_QtrlyReport_Consideration_Limitations.pdf. Accessed May 11, 2007
35.
 California Welfare and Institutions code, section 4500-4519.7: division 4512. http://www.leginfo.ca.gov/cgi-bin/displaycode?section=wic&group=04001-05000&file=4500-4519.7. Accessed May 11, 2007
Original Article
January 2008

Continuing Increases in Autism Reported to California's Developmental Services System: Mercury in Retrograde

Author Affiliations

Author Affiliations: Immunization Branch (Dr Schechter) and California Center for Autism and Developmental Disabilities Research and Epidemiology, Environmental Health Investigations Branch (Dr Grether), California Department of Public Health, Richmond.

Arch Gen Psychiatry. 2008;65(1):19-24. doi:10.1001/archgenpsychiatry.2007.1
Abstract

Context  Previous analyses of autism client data reported to the California Department of Developmental Services (DDS) have been interpreted as supporting the hypothesis that autism is caused by exposure to the preservative thimerosal, which contains ethylmercury. The exclusion of thimerosal from childhood vaccines in the United States was accelerated from 1999 to 2001. The Immunization Safety Review Committee of the Institute of Medicine has recommended surveillance of trends in autism as exposure to thimerosal during early childhood has decreased.

Objective  To determine whether trends in DDS autism client data support the hypothesis that thimerosal exposure is a primary cause of autism.

Design, Setting, and Patients  Study of time trends in the prevalence by age and birth cohort of children with autism who were active status clients of the DDS from January 1, 1995, through March 31, 2007.

Main Outcome Measure  Prevalence of autism among children with active status in the DDS.

Results  The estimated prevalence of autism for children at each year of age from 3 to 12 years increased throughout the study period. The estimated prevalence of DDS clients aged 3 to 5 years with autism increased for each quarter from January 1995 through March 2007. Since 2004, the absolute increase and the rate of increase in DDS clients aged 3 to 5 years with autism were higher than those in DDS clients of the same ages with any eligible condition including autism.

Conclusions  The DDS data do not show any recent decrease in autism in California despite the exclusion of more than trace levels of thimerosal from nearly all childhood vaccines. The DDS data do not support the hypothesis that exposure to thimerosal during childhood is a primary cause of autism.

×